Evidence map›Paper›PMID 38876736›Full record

ArticleThe Lancet. Neurology2024

Concerns with the new biological research criteria for synucleinopathy.

Jennifer G Goldman, Bradley F Boeve, Doug Galasko, James E Galvin, James B Leverenz, John-Paul Taylor

Abstract readLetterComment
In one paragraph

Article in The Lancet. Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  7. Review
  8. Initial biological classification of Lewy body diseases: No consensus on terminology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Jennifer G GoldmanBarrow Neurological Institute, Department of Neurology, Phoenix, AZ 85013, USA; JPG Enterprises, Chicago, IL, USA. Electronic address: drjennifergoldman@gmail.com.
Bradley F BoeveMayo Clinic, Department of Neurology, Rochester, MN, USA.
Doug GalaskoDepartment of Neurosciences, University of California San Diego, San Diego, CA, USA.
James E GalvinComprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA.
James B LeverenzLou Ruvo Center for Brain Health, Neurologic Institute Cleveland Clinic, Cleveland, OH, USA.
John-Paul TaylorMental Health, Dementia and Neurodegeneration Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
NINDS NIH HHS U01 NS100620
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

SynucleinopathiesBiomedical ResearchHumans

Identifiers

PMID38876736
PMCPMC12276888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.